

## CURRICULUM VITAE

|  |  |                |     |
|--|--|----------------|-----|
| <b>Name</b>                              | Ken Blount   | <b>Country</b> | USA |
| <b>Affiliation/<br/>Present Position</b> | Chief Scientific Officer, Rebiotix a Ferring Company & VP Microbiome Research, Ferring Pharmaceuticals |                |     |

### **Education**

Aug 1990 – May 1994 BS University of Arkansas  
Aug 1995 – Jan 2001 PhD University of Colorado

### **Training and Career (Residency and Experience)**

Feb 2001 – Mar 2005 Post-doctoral Fellowship, Univ California San Diego  
Mar 2005 – May 2007 Yale University, Research Scientist  
May 2007 – Dec 2012 BioRelix Inc., Cofounder and Director of Biology  
Aug 2013 – Feb 2015 Yale University Research Scientist  
Feb 2015 – Nov 2016 Yale Cancer Center Research Scientist  
Dec 2016 – present Rebiotix, a Ferring Company; Head of External Res then CSO  
Jan 2021 – present Ferring Pharmaceuticals; VP Microbiome Research

### **Award and Activity**

### **Research Interests**

Microbiota-based therapeutics

### **Bibliography: representative publications from the last three years**

1. Blount et al 2022, Development and Validation of a Novel Microbiome-Based Biomarker for Post-antibiotic Dysbiosis and Subsequent Restoration. *Frontiers in Microbiology* 12: 1-10
2. Khanna et al 2020, RBX7455, a Room Temperature-Stable, Orally-Administered Live Biotherapeutic...*Clinical Infections Diseases* ciaa1430
3. Blount et al 2019, Restoration of Bacterial Microbiome Composition and Diversity...*Open Forum Infectious Diseases* 6:ofz095.ug